SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-214362
Filing Date
2023-08-16
Accepted
2023-08-16 16:47:01
Documents
16
Period of Report
2023-08-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d510715d8k.htm   iXBRL 8-K 29664
2 EX-1.1 d510715dex11.htm EX-1.1 223622
3 EX-5.1 d510715dex51.htm EX-5.1 8677
4 EX-99.1 d510715dex991.htm EX-99.1 6419
8 GRAPHIC g510715g0816042718487.jpg GRAPHIC 2409
  Complete submission text file 0001193125-23-214362.txt   467936

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA antx-20230815.xsd EX-101.SCH 2875
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE antx-20230815_lab.xml EX-101.LAB 18738
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE antx-20230815_pre.xml EX-101.PRE 11724
10 EXTRACTED XBRL INSTANCE DOCUMENT d510715d8k_htm.xml XML 3460
Mailing Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027
Business Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027 (650) 331-9090
AN2 Therapeutics, Inc. (Filer) CIK: 0001880438 (see all company filings)

IRS No.: 820606654 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41331 | Film No.: 231178756
SIC: 2834 Pharmaceutical Preparations